Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender

Pharmacological Research

Volumn 41, Issue 4, 2000, Pages 461-468

  Wala, Elzbieta P ^a   Sloan, Jewell W ^a   Jing, Xin ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dose relationship; Gender; HPLC assay; Pharmacokinetics; PK 11195; Precipitated withdrawal

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENDER; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

EID: 0033839784     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0617     Document Type: Article

References (33)

1. 3H]PK 11195, an isoquinoline carboxamide derivative; Kinetic studies and autoradiographic localization
2. Peripheral benzodiazepine binding sites: Effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarb oxamide
3. The effects of PK 11195, a ligand for benzodiazepine binding sites, in animal tests of anxiety and stress
4. Peripheral-type benzodiazepine receptor ligands and serum steroid hormones
5. Effects of peripheral benzodiazepine receptor ligands on hypothalamic-pituitary-adrenal axis function in the rat
6. The benzodiazepine receptor antagonist PK 11195 alters diazepam-induced changes of tetanic contractions in the rat phrenic nerve-diaphragm preparation
7. The effect of chronic treatment with peripheral benzodiazepine receptor ligands on behavior and GABA(A)/benzodiazepine receptors in rat
8. Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in in-patients with anxious or depressive symptomatology
9. 3) in the tolerance to the electroencephalographic effects of benzodiazepines in rats: Comparison of diazepam and clonazepam
10. Chronic benzodiazepine administration. X. Concurrent administration of the peripheral-type benzodiazepine ligand PK 11195 attenuates chronic effects of lorazepam
11. Chronic benzodiazepine administration XI. Concurrent administration of PK 11195 attenuates lorazepam discontinuation effects
12. Physical dependence on diazepam: Precipitation of abstinence syndromes by peripheral and central benzodiazepine receptor antagonists
13. Comparison of abstinence syndromes precipitated by flumazenil and PK 11195 in female diazepam-dependent rats
14. Diazepam-treated female rats: Flumazenil- and PK 11195-induced withdrawal in the hippocampus CA1
15. Substantia nigra: The involvement of the central and peripheral benzodiazepine receptors in physical dependence on diazepam in rats
16. Intrathecally administered flumazenil and PK 11195 precipitate abstinence syndrome in freely moving diazepam dependent rats
17. PK 11195(PK)-evoked withdrawal in diazepam(DZ)-dependent rats: Effect of dose of PK, DZ and gender
18. Gender differences in behavioral and EEG effects of the central and peripheral benzodiazepine receptors antagonists in the substantia nigra in diazepam-dependent rats
19. Stability and pharmacokinetics of flumazenil in the rat
20. Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat
21. A rapid and simple procedure for chronic cannulation of the rat jugular vein
22. Precipitated abstinence in the diazepam-dependent rat
23. Effect of gender on physical dependence on diazepam in rats
24. Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers
25. Age and gender effects on chlordiazepoxide kinetics: Relation to antipyrine disposition
26. Oxazepam kinetics: Effects of age and gender
27. Effects of the estrous cycle and the gender difference on hepatic drug-metabolising enzyme activities
28. Anatomical distribution of NADPH-cytochrome P450 reductase and cytochrome P4502D forms in rat brain: Effects of xenobiotics and sex steroids
29. Regulation of CYP3A9 gene expression by estrogen and catalytic studies using cytochrome P4503A9 expressed in Escherichia coli
30. Free drug concentration monitoring in clinical practice. Rationale and current status
31. In vivo labelling in several rat tissues of 'peripheral type' benzodiazepine binding sites
32. Pharmacokinetics of the new benzodiazepine antagonist RO 15-1788 in man following intravenous and oral administration